You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 158 No. 9, May 11, 1998 TABLE OF CONTENTS
  Archives
  •  Online Features
  Special Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (81)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Immunologic Disorders
 •Alert me on articles by topic

Guidelines for the Treatment of Cytomegalovirus Diseases in Patients With AIDS in the Era of Potent Antiretroviral Therapy

Recommendations of an International Panel

Richard J. Whitley, MD; Mark A. Jacobson, MD; Dorothy N. Friedberg, MD, PhD; Gary N. Holland, MD; Douglas A. Jabs, MD; Douglas T. Dieterich, MD; W. David Hardy, MD; Michael A. Polis, MD, MPH; Thomas A. Deutsch, MD; Judith Feinberg, MD; Stephen A. Spector, MD; Sharon Walmsley, MD, FRCPC; W. Lawrence Drew, MD, PhD; William G. Powderly, MD; Paul D. Griffiths, MD; Constance A. Benson, MD; Harold A. Kessler, MD; for the International AIDS Society–USA

Arch Intern Med. 1998;158:957-969.

Objective  To provide recommendations for the treatment of acquired immunodeficiency syndrome–related cytomegalovirus (CMV) end-organ diseases, including retinitis, colitis, pneumonitis, and neurologic diseases.

Participants  A 17-member panel of physicians with expertise in clinical and virological research and in-patient care in the field of CMV diseases.

Evidence  Available clinical and virological study results. Recommendations are rated according to the quality and strength of available evidence. Recommendations were limited to the treatment of CMV diseases; prophylaxis recommendations are not included.

Process  The panel was convened in February 1997 and met regularly through November 1997. Subgroups of the panel summarized and presented available information on specific topics to the full panel; recommendations and ratings were determined by group consensus.

Conclusions  Although the epidemiological features of CMV diseases are changing in the setting of potent, combination antiretroviral therapy, continued attention must be paid to CMV diseases in patients infected with the human immunodeficiency virus to prevent irreversible end-organ dysfunction. The initial and maintenance treatment of CMV retinitis must be individualized based on the characteristics of the lesions, including location and extent, specific patient factors, and characteristics of available therapies among others. Management of relapse or refractory retinitis must be likewise individualized. Ophthalmologic screening for patients at high risk for retinitis or who have a prior diagnosis of extraretinal disease is recommended. Recommendations for gastrointestinal, pulmonary, and neurologic manifestations are included.


From the University of Alabama at Birmingham School of Medicine (Dr Whitley); University of California, San Francisco, School of Medicine (Drs Jacobson and Drew); New York University School of Medicine, New York (Drs Dieterich and Friedberg); University of California, Los Angeles, School of Medicine (Drs Holland and Hardy); Johns Hopkins University School of Medicine, Baltimore, Md (Dr Jabs); National Institute of Allergy and Infectious Diseases, Bethesda, Md (Dr Polis); Rush Medical College, Chicago, Ill (Drs Deutsch, Benson, and Kessler); University of Cincinnati College of Medicine, Cincinnati, Ohio (Dr Feinberg); University of California, San Diego (Dr Spector); University of Toronto Department of Medicine, Toronto, Ontario (Dr Walmsley); Washington University School of Medicine, St Louis, Mo (Dr Powderly); and Royal Free Hospital School of Medicine, London, England (Dr Griffiths). Dr Benson is now with the Division of Infectious Disease, University of Colorado School of Medicine, Denver.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Successful treatment of CMV ventriculitis immune reconstitution syndrome
Janowicz et al.
J. Neurol. Neurosurg. Psychiatry 2005;76:891-892.
FULL TEXT  

Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome
Kishore et al.
J Med Microbiol 2004;53:1155-1160.
ABSTRACT | FULL TEXT  

Perianal Ulcer in a Patient With AIDS--Diagnosis
Arch Dermatol 2004;140:877-882.
FULL TEXT  

Measurement of Human Cytomegalovirus Loads by Quantitative Real-Time PCR for Monitoring Clinical Intervention in Transplant Recipients
Li et al.
J. Clin. Microbiol. 2003;41:187-191.
ABSTRACT | FULL TEXT  

Risk Factors for Advancement of Cytomegalovirus Retinitis in Patients With Acquired Immunodeficiency Syndrome
Holbrook et al.
Arch Ophthalmol 2000;118:1196-1204.
ABSTRACT | FULL TEXT  

Comparative Study of the Anti-Human Cytomegalovirus Activities and Toxicities of a Tetrahydrofuran Phosphonate Analogue of Guanosine and Cidofovir
Bedard et al.
Antimicrob. Agents Chemother. 1999;43:557-567.
ABSTRACT | FULL TEXT  

Intractable Diarrhea From Cytomegalovirus Enterocolitis in an Immunocompetent Infant
Fox et al.
Pediatrics 1999;103:e10-10.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.